How Boston Scientific’s Alair System Performed in Trials
BSX’s Alair System
Boston Scientific’s Alair Bronchial Thermoplasty System is used to treat patients suffering from severe asthma. The system was approved by the FDA (US Food and Drug Administration) in 2010 and has been one of the company’s leading products. It is the first “non-pharmacologic, device-based treatment” for patients suffering from severe, persistent asthma.
Interested in BSX? Don't miss the next report.
Receive e-mail alerts for new research on BSX
As per the company, “The Alair System delivers controlled thermal energy to the airway wall to reduce the amount of excess smooth muscle tissue in the airways. With less smooth muscle, the airways constrict less, reducing severe asthma attacks and making breathing easier.”
Post approval study details
The PAS2 study that is a post-approval clinical trial evaluating bronchial thermoplasty in severe persistent asthma patients who underwent treatment with BSX’s Alair system. The study data has shown reduced complications in patients.
The PAS2 study was an open-label study. It took place at 27 centers across the United States and Canada and included 284 patients. The patients who underwent treatment will be further evaluated for five years after treatment.
According to the study results, patients on high doses of medications experienced significant improvement in their condition following the bronchial thermoplasty procedure and proved the safety and efficacy of the treatment. As per the study results, “The percentage of study participants that had at least one severe asthma exacerbation decreased from 77.8 percent in the year prior to treatment to 50.4 percent in year one and 46.4 percent in year two.”
Various other companies in the medical device companies such as Abbott Laboratories (ABT), Medtronic (MDT), and Becton Dickinson (BDX) haven’t yet entered this lucrative space. Investors who want to gain exposure to Boston Scientific can invest in the Vanguard Total Stock Market ETF (VTI), which holds ~0.15% of its total holdings in BSX.